Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The relative efficacy and safety of intravitreous aflibercept, bevacizumab, and ranibizumab in the treatment of diabetic macular edema are unknown. METHODS: At 89 clinical sites, we randomly assigned 660 adults (mean age, 61±10 years) with diabetic macular edema involving the macular center to receive intravitreous aflibercept at a dose of 2.0 mg (224 participants), bevacizumab at a dose of 1.25 mg (218 participants), or ranibizumab at a dose of 0.3 mg (218 participants). The study drugs were administered as often as every 4 weeks, according to a protocol-specified algorithm. The primary outcome was the mean change in visual acuity at 1 year. RESULTS: From baseline to 1 year, the mean visual-acuity letter score (range, 0 to 100, with higher scores indicating better visual acuity; a score of 85 is approximately 20/20) improved by 13.3 with aflibercept, by 9.7 with bevacizumab, and by 11.2 with ranibizumab. Although the improvement was greater with aflibercept than with the other two drugs (P<0.001 for aflibercept vs. bevacizumab and P=0.03 for aflibercept vs. ranibizumab), it was not clinically meaningful, because the difference was driven by the eyes with worse visual acuity at baseline (P<0.001 for interaction). When the initial visual-acuity letter score was 78 to 69 (equivalent to approximately 20/32 to 20/40) (51% of participants), the mean improvement was 8.0 with aflibercept, 7.5 with bevacizumab, and 8.3 with ranibizumab (P>0.50 for each pairwise comparison). When the initial letter score was less than 69 (approximately 20/50 or worse), the mean improvement was 18.9 with aflibercept, 11.8 with bevacizumab, and 14.2 with ranibizumab (P<0.001 for aflibercept vs. bevacizumab, P=0.003 for aflibercept vs. ranibizumab, and P=0.21 for ranibizumab vs. bevacizumab). There were no significant differences among the study groups in the rates of serious adverse events (P=0.40), hospitalization (P=0.51), death (P=0.72), or major cardiovascular events (P=0.56). CONCLUSIONS: Intravitreous aflibercept, bevacizumab, or ranibizumab improved vision in eyes with center-involved diabetic macular edema, but the relative effect depended on baseline visual acuity. When the initial visual-acuity loss was mild, there were no apparent differences, on average, among study groups. At worse levels of initial visual acuity, aflibercept was more effective at improving vision. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT01627249.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
(2007) · Developments in Ophthalmology · doi:10.1159/isbn.978-3-318-01439-6 · Cited by 5,583
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Schafer, J. L. (1999) · Statistical Methods in Medical Research · doi:10.1177/096228029900800102 · Cited by 3,949
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Easy SAS Calculations for Risk or Prevalence Ratios and Differences
Spiegelman, D. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi188 · Cited by 1,738
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Ranibizumab for Diabetic Macular Edema
Nguyen, Q. D., Brown, D. M., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Gibson, A., Sy, J., Rundle, A. C., Hopkins, J. J., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.12.039 · Cited by 1,621
Research works printed but not linked: 4
- 10.1097/IAE.0b013e3182695b83 · doi:10.1097/iae.0b013e3182695b83
- 10.1191/096228099671525676 · DOI
- Virgili G, 2014, Cochrane Database Syst Rev, 10, CD007419
- Moja L, 2014, Cochrane Database Syst Rev, 9, CD011230
Cited by
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Abràmoff, M. D., Lavin, P. T., Birch, M., Shah, N., & Folk, J. C. (2018) · npj Digital Medicine · doi:10.1038/s41746-018-0040-6 · Cited by 1,638
Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss
Lee, R., Wong, T. Y., & Sabanayagam, C. (2015) · Eye and Vision · doi:10.1186/s40662-015-0026-2 · Cited by 1,569
Diabetic Retinopathy: Pathophysiology and Treatments
Wang, W., & Lo, A. C. Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061816 · Cited by 1,358
Wong, T. Y., Cheung, C. M. G., Larsen, M., Sharma, S., & Simó, R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.12 · Cited by 1,094
Ting, D. S. W., Cheung, G. C. M., & Wong, T. Y. (2016) · Clinical & Experimental Ophthalmology · doi:10.1111/ceo.12696 · Cited by 1,066
Diabetic retinopathy: current understanding, mechanisms, and treatment strategies
Duh, E. J., Sun, J. K., & Stitt, A. W. (2017) · JCI Insight · doi:10.1172/jci.insight.93751 · Cited by 1,057
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
Wells, J. A., Glassman, A. R., Ayala, A. R., Jampol, L. M., Bressler, N. M., Bressler, S. B., Brucker, A. J., Ferris, F. L., Hampton, G. R., Jhaveri, C., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.02.022 · Cited by 1,051
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
Diabetic Retinopathy: A Position Statement by the American Diabetes Association
Solomon, S. D., Chew, E., Duh, E. J., Sobrin, L., Sun, J. K., VanderBeek, B. L., Wykoff, C. C., & Gardner, T. W. (2017) · Diabetes Care · doi:10.2337/dc16-2641 · Cited by 940
Guidelines on Diabetic Eye Care
Wong, T. Y., Sun, J., Kawasaki, R., Ruamviboonsuk, P., Gupta, N., Lansingh, V. C., Maia, M., Mathenge, W., Moreker, S., Muqit, M. M. K., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.04.007 · Cited by 839
Intravitreal Aflibercept for Diabetic Macular Edema
Korobelnik, J.-F., Do, D. V., Schmidt-Erfurth, U., Boyer, D. S., Holz, F. G., Heier, J. S., Midena, E., Kaiser, P. K., Terasaki, H., Marcus, D. M., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.006 · Cited by 816
Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross, J. G., Glassman, A. R., Jampol, L. M., Inusah, S., Aiello, L. P., Antoszyk, A. N., Baker, C. W., Berger, B. B., Bressler, N. M., et al. (2015) · JAMA · doi:10.1001/jama.2015.15217 · Cited by 784
Artificial intelligence in retina
Schmidt-Erfurth, U., Sadeghipour, A., Gerendas, B. S., Waldstein, S. M., & Bogunović, H. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.07.004 · Cited by 779
Diabetic Retinopathy Preferred Practice Pattern®
Flaxel, C. J., Adelman, R. A., Bailey, S. T., Fawzi, A., Lim, J. I., Vemulakonda, G. A., & Ying, G.-S. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.09.025 · Cited by 717
Schmidt-Erfurth, U., Garcia-Arumi, J., Bandello, F., Berg, K., Chakravarthy, U., Gerendas, B. S., Jonas, J., Larsen, M., Tadayoni, R., & Loewenstein, A. (2017) · Ophthalmologica · doi:10.1159/000458539 · Cited by 703
Current understanding of the molecular and cellular pathology of diabetic retinopathy
Antonetti, D. A., Silva, P. S., & Stitt, A. W. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00451-4 · Cited by 645
Intravitreal Aflibercept for Diabetic Macular Edema
Brown, D. M., Schmidt-Erfurth, U., Do, D. V., Holz, F. G., Boyer, D. S., Midena, E., Heier, J. S., Terasaki, H., Kaiser, P. K., Marcus, D. M., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.06.017 · Cited by 623
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
LeRoith, D., Biessels, G. J., Braithwaite, S. S., Casanueva, F. F., Draznin, B., Halter, J. B., Hirsch, I. B., McDonnell, M. E., Molitch, M. E., Murad, M. H., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00198 · Cited by 568
Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets
Das, A., McGuire, P. G., & Rangasamy, S. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.03.024 · Cited by 545
Wykoff, C. C., Abreu, F., Adamis, A. P., Basu, K., Eichenbaum, D. A., Haskova, Z., Lin, H., Loewenstein, A., Mohan, S., Pearce, I. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00018-6 · Cited by 504
Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy
Lin, K., Hsih, W., Lin, Y., Wen, C., & Chang, T. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13480 · Cited by 446
Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory
Romero-Aroca, P., Baget-Bernaldiz, M., Pareja-Rios, A., Lopez-Galvez, M., Navarro-Gil, R., & Verges, R. (2016) · Journal of Diabetes Research · doi:10.1155/2016/2156273 · Cited by 404
Tan, G. S., Cheung, N., Simó, R., Cheung, G. C. M., & Wong, T. Y. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30052-3 · Cited by 361
VEGFR1 signaling in retinal angiogenesis and microinflammation
Uemura, A., Fruttiger, M., D'Amore, P. A., De Falco, S., Joussen, A. M., Sennlaub, F., Brunck, L. R., Johnson, K. T., Lambrou, G. N., Rittenhouse, K. D., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100954 · Cited by 354
Avery, R. L., Castellarin, A. A., Steinle, N. C., Dhoot, D. S., Pieramici, D. J., See, R., Couvillion, S., Nasir, M. A., Rabena, M. D., Maia, M., et al. (2017) · Retina · doi:10.1097/iae.0000000000001493 · Cited by 352
Samara, W. A., Shahlaee, A., Adam, M. K., Khan, M. A., Chiang, A., Maguire, J. I., Hsu, J., & Ho, A. C. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2016.10.008 · Cited by 345
Bressler, N. M., Beaulieu, W. T., Glassman, A. R., Blinder, K. J., Bressler, S. B., Jampol, L. M., Melia, M., Wells, J. A., & for the Diabetic Retinopathy Clinical Research Network (2018) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2017.6565 · Cited by 343
Microglia and Inflammatory Responses in Diabetic Retinopathy
Kinuthia, U. M., Wolf, A., & Langmann, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.564077 · Cited by 321
Targeting angiogenesis in oncology, ophthalmology and beyond
Cao, Y., Langer, R., & Ferrara, N. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00671-z · Cited by 315
Angiogenesis and Inflammation Crosstalk in Diabetic Retinopathy
Capitão, M., & Soares, R. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25575 · Cited by 312
Sun, Z., Tang, F., Wong, R., Lok, J., Szeto, S. K. H., Chan, J. C. K., Chan, C. K. M., Tham, C. C., Ng, D. S., & Cheung, C. Y. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.06.016 · Cited by 307
Baker, C. W., Glassman, A. R., Beaulieu, W. T., Antoszyk, A. N., Browning, D. J., Chalam, K. V., Grover, S., Jampol, L. M., Jhaveri, C. D., Melia, M., et al. (2019) · JAMA · doi:10.1001/jama.2019.5790 · Cited by 299
Donaghue, K. C., Marcovecchio, M. L., Wadwa, R. P., Chew, E. Y., Wong, T. Y., Calliari, L. E., Zabeen, B., Salem, M. A., & Craig, M. E. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12742 · Cited by 298
Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain
Hamilton, J. L., Nagao, M., Levine, B. R., Chen, D., Olsen, B. R., & Im, H.-J. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2828 · Cited by 287
Sahni, J., Patel, S. S., Dugel, P. U., Khanani, A. M., Jhaveri, C. D., Wykoff, C. C., Hershberger, V. S., Pauly-Evers, M., Sadikhov, S., Szczesny, P., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.03.023 · Cited by 285
Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia
Xue, K., Jolly, J. K., Barnard, A. R., Rudenko, A., Salvetti, A. P., Patrício, M. I., Edwards, T. L., Groppe, M., Orlans, H. O., Tolmachova, T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0185-5 · Cited by 185
12. Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s012 · Cited by 177
12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gibbons, C. H., Giurini, J. M., Hilliard, M. E., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s012 · Cited by 169
12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Callaghan, B. C., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s012 · Cited by 176
Artificial intelligence promotes the diagnosis and screening of diabetic retinopathy
Huang, X., Wang, H., She, C., Feng, J., Liu, X., Hu, X., Chen, L., & Tao, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.946915 · Cited by 115
Artificial Intelligence in Diabetic Eye Disease Screening
(2019) · Asia-Pacific Journal of Ophthalmology · doi:10.22608/apo.201976 · Cited by 82
Teo, Z. L., Tham, Y.-C., Yu, M., Cheng, C.-Y., Wong, T. Y., & Sabanayagam, C. (2020) · Eye · doi:10.1038/s41433-020-0776-5 · Cited by 62
Use of rabbit eyes in pharmacokinetic studies of intraocular drugs
Ahn, S. J., Hong, H. K., Na, Y. M., Park, S. J., Ahn, J., Oh, J., Chung, J. Y., Park, K. H., & Woo, S. J. (2016) · Journal of Visualized Experiments · doi:10.3791/53878 · Cited by 60
Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema
Barakat, M. R., Wykoff, C. C., Gonzalez, V., Hu, A., Marcus, D., Zavaleta, E., & Ciulla, T. A. (2021) · Ophthalmology Retina · doi:10.1016/j.oret.2020.08.007 · Cited by 55
Patel, D., Ananthakrishnan, A., Lin, T., Channa, R., Liu, T. Y. A., & Wolf, R. M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237120 · Cited by 43
Shi, H., Zhu, Y., Xing, C., Li, S., Bao, Z., Lei, L., Lin, D., Wang, Y., Chen, H., & Xu, X. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122081 · Cited by 29
Improving Biopharmaceutical Safety Through Verification‐Based Quality Control
Yu, Y. B., Taraban, M. B., Wang, W., & Briggs, K. T. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2017.08.010 · Cited by 23
Cai, C. X., Nishimura, A., Bowring, M. G., Westlund, E., Tran, D., Ng, J. H., Nagy, P., Cook, M., McLeggon, J.-A., DuVall, S. L., et al. (2024) · Ophthalmology Retina · doi:10.1016/j.oret.2024.03.014 · Cited by 20
Saving sight in China and beyond: the Lifeline Express model
Wong, I. Y. H., Ni, M. Y., Wong, I. O. L., Fong, N., & Leung, G. M. (2018) · BMJ Global Health · doi:10.1136/bmjgh-2018-000766 · Cited by 19
Fu, D. J., Mishra, A. V., Quek, C., Balaskas, K., Pontikos, N., Sim, D., Sivaprasad, S., & Faes, L. (2025) · Eye · doi:10.1038/s41433-024-03529-9 · Cited by 14
Hertzberg, S. N. W., Jørstad, Ø. K., Petrovski, B. É., Bragadottir, R., Steffensen, L. A., Moe, M. C., Burger, E. A., & Petrovski, G. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191912603 · Cited by 6
Metadata
- Authors
- The Diabetic Retinopathy Clinical Research Network
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-03-26
- Volume
- 372
- Issue
- 13
- Pages
- 1193-1203
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1786299986
- Cited by
- 1,607
- References
- 35
- FWCI
- 160.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.